Maternal immunization against some infectious diseases can offer significant advantages for women, preventing maternal morbidity and mortality, or for offspring, preventing fetal disease and conferring passive immunity to neonates. Recently, clinical trials specifically to evaluate the immunogenicity, safety, and tolerability of some of the available coronavirus disease 2019 (COVID-19) vaccines in pregnant and lactating women have been planned, initiated and, in some cases, completed. This paper discusses whether the immunization of pregnant women against COVID-19 is justified and presents knowledge about the immunogenicity and safety of mRNA COVID-19 vaccines for these subjects. The results of recent studies indicate that pregnant women are at increased risk of developing severe disease compared with nonpregnant women of the same age. Studies carried out with mRNA vaccines indicate that the immunogenicity, safety and tolerability of these preventive measures in pregnant women are not different from those in nonpregnant women of the same age. Moreover, antibodies are efficiently transferred through the placenta and can be detected in breastmilk, suggesting a potential prevention of infection in the child. All these findings authorize the use of mRNA vaccines in pregnant women to protect both the mother and the child. However, further studies with larger sample size and with follow-up of the pregnant women vaccinated during different periods of pregnancy and their children are needed to better characterize the immune response of pregnant women, to define when these vaccines should be administered to obtain the best protection, and to measure vaccine efficacy against virus variants in both mothers and infants. COVID-19 vaccines based on different technological platforms cannot presently be used, and their role in pregnant women should be clarified.
【저자키워드】 COVID-19, COVID-19 vaccine, Pregnancy, maternal immunization, Mother-to-child transmission, 【초록키워드】 coronavirus disease, Efficacy, Vaccine, immune response, clinical trial, Placenta, antibody, mRNA vaccine, knowledge, children, Infection, passive immunity, Infectious disease, immunization, pregnant women, Infants, Maternal, Neonates, age, morbidity and mortality, breastmilk, Follow-up, women, disease, platform, mother, pregnant, severe disease, preventive measure, mRNA COVID-19 vaccine, Tolerability, Sample size, increased risk, offspring, offer, Administered, lactating women, PROTECT, evaluate, carried, subjects, initiated, to define, not different, fetal, nonpregnant, transferred, virus variant,